Glow-in-the-Dark dye could help surgeons find hidden tumors in kids
NCT ID NCT06915727
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This phase 3 trial tests whether a fluorescent dye called pafolacianine can help surgeons see cancerous tissue during surgery in children aged 6 months to 17 years with solid tumors. The dye targets folate receptors, which are common on many cancer cells, and lights up under a special near-infrared camera. The study aims to improve how completely tumors are removed by making them more visible during the operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pafolacianine (Cytalux), a fluorescent imaging agent given intravenously
What this could lead to
If successful, this could give surgeons a real-time tool to more completely remove tumors during surgery, potentially improving outcomes for children with solid cancers.
What could go wrong
This is a small, early-phase trial with only 20 children, so results may not apply broadly. The dye's accuracy in detecting all tumor cells is still unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.